Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

David Moon

Physician Assistant Henrico, VA Physician Assistant

NPI 1538469465 CMS profile 10512560

9920 Independence Park Dr Ste 100, Henrico, VA 23233

Open in the dashboard

General payments

$11,512

586 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Moon of Henrico, VA is reported in the CMS Open Payments database as having received $11,512 across 586 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,484 122
2024 General $2,996 130
2023 General $2,498 128
2022 General $2,151 113
2021 General $1,382 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Moon
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to David Moon were reported at $2,484. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year David Moon Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,382 $132 $37–$438 $132
2022 $2,151 $155 $48–$522 $149
2023 $2,498 $167 $52–$557 $160
2024 $2,996 $178 $55–$600 $164
2025 $2,484 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $1,843 64 payments
  2. Regeneron Healthcare Solutions, Inc. $1,258 63 payments
  3. GlaxoSmithKline, LLC. $1,087 85 payments
  4. Amgen Inc. $947 38 payments
  5. Genzyme Corporation $797 43 payments
  6. Novartis Pharmaceuticals Corporation $756 41 payments
  7. Genentech USA, Inc. $723 45 payments
  8. CSL Behring $631 31 payments
  9. kaleo, Inc. $439 24 payments
  10. OptiNose US, Inc. $424 19 payments
  11. Other $2,608 133 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,170 579 payments
  2. Education $342 7 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,668 88 payments
  2. TEZSPIRE Inflammation $888 35 payments
  3. DUPIXENT Inflammation And Immunology $803 48 payments
  4. NUCALA $769 55 payments
  5. Xolair $723 45 payments
  6. TEZSPIRE Respiratory $654 21 payments
  7. FASENRA $625 26 payments
  8. BREZTRI $597 7 payments
  9. Haegarda $454 21 payments
  10. AIRSUPRA $444 11 payments
  11. Other $4,982 270 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

586

Median for Physician Assistant: 241

Drug cost

$77,702

Median for Physician Assistant: $4,110

Branded share of claims

34.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 40 $30,246
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 12 $8,681
Breo Ellipta Fluticasone/Vilanterol Brand 18 $7,350
Qvar Redihaler Beclomethasone Dipropionate Brand 16 $7,006
Symbicort Budesonide/Formoterol Fumarate Brand 17 $5,795
Epinephrine Generic 20 $3,522
Wixela Inhub Fluticasone Propion/Salmeterol Brand 24 $2,857
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 24 $2,766
Azelastine Hcl Generic 90 $2,756
Ipratropium Bromide Generic 50 $1,817

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$2,843

Medicare's payments for the services billed

Medicare patients

28

Average age 72

Services billed

133

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • Amgen Inc. $349
  • AstraZeneca Pharmaceuticals LP $216
$565 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $341
  • GENZYME CORPORATION $123
  • SANOFI-AVENTIS U.S. LLC $55
$519 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $177
  • Genentech USA, Inc. $171
$348 — —
Haegarda
  • CSL Behring $183
$183 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $165
$165 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

586 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record